SCHEMBL4766562

SCHEMBL4766562

CCN1CCN(Cc2ccc(-c3cc4c(Nc5ccc(OCc6ccccc6)cc5)ncnc4[nH]3)cc2)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 14/20 0.69
EGFR P00533 4/20 0.64
KDR P35968 2/20 0.64
STK10 O94804 1/20 0.64
MAP4K4 O95819 1/20 0.64
ABL1 P00519 1/20 0.64
ERBB2 P04626 1/20 0.64
YES1 P07947 1/20 0.64
RET P07949 1/20 0.64
PDGFRB P09619 1/20 0.64
BCR P11274 1/20 0.64
FLT1 P17948 1/20 0.64
ERBB3 P21860 1/20 0.64
WEE1 P30291 1/20 0.64
ABL2 P42684 1/20 0.64
NEK3 P51956 1/20 0.64
LIMK1 P53667 1/20 0.64
LIMK2 P53671 1/20 0.64
EPHB4 P54760 1/20 0.64
ACVR1 Q04771 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4763910 0.93 PRMT5 (0.66) PRMT5EGFRKDRSTK10MAP4K4
SCHEMBL4764020 0.92 EGFR (0.60) PRMT5EGFRKDRSTK10MAP4K4
SCHEMBL4771238 0.91 EGFR (0.59) PRMT5EGFRKDRSTK10MAP4K4
SCHEMBL4764456 0.90 PRMT5 (0.66) PRMT5EGFRAURKBINCENP
SCHEMBL4764644 0.87 PRMT5 (0.67) PRMT5EGFRAURKBINCENPTTBK1
SCHEMBL4763947 0.85 PRMT5 (0.64) PRMT5EGFRERBB2ERBB4AURKB
SCHEMBL4768646 0.84 EGFR (0.61) PRMT5EGFRERBB2ERBB4AURKB
SCHEMBL4764558 0.84 EGFR (0.63) PRMT5EGFRERBB2ERBB4AURKB
SCHEMBL30571364 0.82 PRMT5 (1.00) PRMT5KDR
SCHEMBL4770678 0.81 KDR (0.59) PRMT5EGFRKDRSTK10MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1416935-B1 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2008-03-12 EP claimed
US-7244729-B2 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives NOVARTIS AG (CH) 2007-07-17 US claimed
US-20040248911-A1 7H-pyrrolo[2,3-d]pyrimidine derivatives BOLD GUIDO (CH) 2004-12-09 US claimed
US-20040242600-A1 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives NOVARTIS AG (CH) 2004-12-02 US claimed
EP-1416935-B1 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2008-03-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248911-A1 7H-pyrrolo[2,3-d]pyrimidine derivatives DPYD, DHPS, TYMP PRMT5 684/4885EGFR 3391/4885KDR 3031/4885
US-20040242600-A1 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives DPYD, TYMP, TYMS PRMT5 345/4885EGFR 2694/4885KDR 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.